Povidone-Iodine Rinses in the Management of COVID-19
Covid19
About this trial
This is an interventional treatment trial for Covid19 focused on measuring Povidone - Iodine, Covid19, Self-Isolation
Eligibility Criteria
Inclusion Criteria:
- 19 years or older
- Patients diagnosed with laboratory-confirmed SARS-CoV-2 and the development of COVID-19 compatible symptoms within the last 72 hours before enrolment
- Do not require hospitalization
Exclusion Criteria:
- Sinonasal tumor
- Hypersensitivity to iodine or betadine
- History of thyroid disorder including thyroid cancer, hyperthyroidism and hypothyroidism
- Use of medications for thyroid disorders including thyroxine and carbimazole
- Current use of topical iodine or betadine for another reason
- Participating in any study with therapies directed at COVID-19 that could influence our results
- Are pregnant or breastfeeding
Sites / Locations
- St. Paul's Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Placebo Comparator
Experimental
PVP-I sinus rinses and throat gargles
Placebo sinus rinses and throat gargles
PVP-I gel forming nasal spray
Participants will dilute 7 mL of 10% PVP-I into 300 mL of saline for a final concentration of 0.23% available iodine. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
Participants will dilute 7 mL of PVP-I placebo into 300 mL of saline. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
0.6% PVP-I gel forming nasal spray will come prepared and ready for participants to use. They will be instructed to use two sprays to each nostril each time they administer the spray.